Premium
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study
Author(s) -
Marchesini Gessica,
Nadali Gianpaolo,
Facchinelli Davide,
Candoni Anna,
Cattaneo Chiara,
Laurenti Luca,
Fanci Rosa,
Farina Francesca,
Lessi Federica,
Visentin Andrea,
Marchesi Francesco,
Prezioso Lucia,
Spolzino Angelica,
Tisi Maria Chiara,
Trastulli Fabio,
Picardi Marika,
Verga Luisa,
Dargenio Michelina,
Busca Alessandro,
Pagano Livio
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17145
Subject(s) - ibrutinib , idelalisib , medicine , lymphoproliferative disorders , lymphoma , immunology , gastroenterology , leukemia , chronic lymphocytic leukemia
Summary We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P < 0·001). Although a higher rate of IFD was observed in patients treated with ibrutinib, the difference was not statistically significant (13·7% vs. 3·8% respectively; P = 0·18). Bacteria are the most frequent infections with ibrutinib, while viruses are most frequently involved with idelalisib.